Pitavastatin and 4'-Hydroxy-3'-Methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes

Current Neurovascular Research

Volumn 7, Issue 3, 2010, Pages 180-191

  Sharma, Bhupesh ^a   Singh, Nirmal ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Dementia; Diabetes; Donepezil; Endothelial dysfunction; Morris water maze; NADPH oxidase; Statin; Streptozotocin

Indexed keywords

ACETYLCHOLINESTERASE; APOCYNIN; DONEPEZIL; GLUCOSE; GLUTATHIONE; NITRATE; NITRITE; PITAVASTATIN; PROTEIN; STREPTOZOCIN; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BODY WEIGHT; BRAIN; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; LEARNING; LOW DRUG DOSE; MALE; MAZE TEST; MEMORY; MULTIINFARCT DEMENTIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

EID: 77956546678     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720210792231831     Document Type: Article

References (76)

1. Parle M, Singh N. Reversal of memory deficits by atorvastatin and simvastatin in rats. Yakugaku Zasshi 2007; 127: 1125-37.
2. Cacbelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatr Clin Neurosci 2008; 258 (1): 28-47.
3. Schneck M.J. Vascular dementia. Top Stroke Rehabil 2008; 15 (1): 22-6.
4. Jellinger K.A. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropatholog 2007; 113 (4): 349-88.
5. Swartz RH, Stuss DT, Gao F, Black S.E. Independent cognitive effects of atrophy and diffuse subcortical and thalamico-cortical cerebrovascular disease in dementia. Stroke 2008; 39 (3): 822-30.
6. Bomboi G, Castello L, Cosentino F, Giubilei F, Orzi F, Volpe M. Alzheimer's disease and endothelial dysfunction. Neurol Sci 2010; 31(1): 1-8.
7. Kearney-Schwartz A, Rossignol P, Bracard S, et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke 2009; 40(4): 1229-36.
8. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and risk of Alzheimer's disease in late onset families. Science 1993; 26: 921-3.
9. de la Torre J.C. Alzheimer's disease prevalence can be lowered with non-invasive testing. J Alzheimers Dis 2008; 14(3): 353-9.
10. Takeda S, Sato N, Ogihara T, Morishita R. The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: New therapeutic potential. Front Biosci 2008; 13: 2253-65.
11. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 2004; 26: 1044-80.
12. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 2006; 5(1): 64-74. (Pubitemid 41790697)
13. Kloppenborg RP, Berg EVD, Kappelle LJ, Biessels G.J. Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic review. Eur J Pharmacol 2008; 585(1): 97-108.
14. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999; 52(5): 971-5.
15. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61(5): 661-6.
16. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 2007; 56(1): 211-6.
17. Lambeth J.D. Nox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropy. Free Radic Biol Med 2007; 43 (3): 332-47.
18. Maldonado PD, Molina-Jijón E, Villeda-Hernández J, Galván- Arzate S, Santamaría A, Pedraza-Chaverrí J. NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic / prooxidant model of Huntington's disease in rats: Protective role of apocynin. J Neurosci Res 2010; 88(3): 620-9.
19. Block M.L. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 2008; 9 (2): S8.
20. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol 2006; 26 (4): 826-32.
21. Iadecola C, Park L, Capone C. Threats to the mind: Aging, amyloid, and hypertension. Stroke 2009; 40(3): S40-4.
22. Miida T, Takahashi A, Ikeuchi T. Prevention of stroke and dementia by statin therapy: Experimental and clinical evidence of their pleiotropic effects. Pharmacol Ther 2007; 113: 378-93.
23. Sharma B, Singh N, Singh M. Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil. J Psychopharmacol 2008; 22(2): 162-71.
24. Koladiya RU, Jaggi AS, Singh N, Sharma B.K. Ameliorative role of atorvastatin and pitavastatin in l-methionine induced vascular dementia in rats. BMC Pharmacol 2008; 8: 14.
25. Brosky G, Logothetopoulos J. Streptozotocin diabetes in the mouse and guinea pig. Diabetes 1969; 18(9): 606-11.
26. Rakieten N, Rakieten ML, Nandkarni M.V. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963; 29: 91-8.
27. Morris RG.M. Developments of a water maze producer for studying spatial learning in the rats. J Neurosci Methods 1984; 11: 47-60.
28. Sharma B, Singh N, Singh M, Jaggi A.S. Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. Pharmacol Biochem Behav 2008; 89(4): 535-45.
29. Pieper G.M. Diabetic induced endothelial dysfunction in rat aorta: Role of hydroxyl radicals. Cardiovasc Res 1997; 34: 145-56.
30. Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao G.S. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem 2002; 306(1): 79-82.
31. Wang HD, Pagano PJ, Du Y. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 1998; 82: 810-8.
32. Ellman GL, Courtney DK, Andres V, Feathstone R.M. A new and rapid colorimeteric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
33. Voss G, Sachsse K. Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by a modified acetylthiocholine / DTNB procedure. Toxicol Appl Pharmacol 1970; 16: 764-72.
34. Ohokawa H, Ohishi N, Yagi K. Assay for lipid peroxided in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-8.
35. Beutler E, Duron O, Kelly B. Reduced glutathione estimation. J Lab Clin Med 1963; 61: 82.
36. Lowry OH, Rosebrough NJ, Far AL, Randall R.J. Protein measurement with folin- phenol reagent. J Biol Chem 1951; 193: 265-75.
37. Chopra K, Tiwari V, Arora V, Kuhad A. Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy. J Pain 2010; [Epub ahead of print].
38. Marotta F, Harada M, Dallah ED, et al. Protective effect of a polyphytocompound on early stage nephropathy secondary to experimentally-induced diabetes. J Biol Regul Homeost Agents 2010; 24(1): 41-9.
39. Huynh K, McMullen JR, Julius TL, et al. Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 2010; 59(6): 1512-20.
40. Feng B, Chen S, George B, Feng Q, Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010; 26 (1): 40-9.
41. Olukman M, Orhan CE, Celenk FG, Ulker S. Apocynin restores endothelial dysfunction in streptozotocin diabetic rats through regulation of nitric oxide synthase and NADPH oxidase expressions. J Diabetes Complications 2010; [Epub ahead of print]
42. Zhang T, Pan BS, Sun GC, Sun X, Sun F.Y. Diabetes synergistically exacerbates poststroke dementia and tau abnormality in brain. Neurochem Int 2010; 56(8): 955-61.
43. Rao VR, Prescott E, Shelke NB, et al. Delivery of SAR 1118 to Retina Via Ophthalmic Drops and its Effectiveness in Reduction of Retinal Leukostasis and Vascular Leakiness in Rat Streptozotocin (STZ) Model of Diabetic Retinopathy (DR). Invest Ophthalmol Vis Sci 2010; [Epub ahead of print].
44. Yohannes E, Chang J, Tar MT, Davies KP, Chance M.R. Molecular targets for diabetes mellitus-associated erectile dysfunction. Mol Cell Proteomics 2010; 9(3): 565-78.
45. Schafer A, Vogt C, Fraccarollo D, et al. Eplerenone improves vascular function and reduces platelet activation in diabetic rats. J Physiol Pharmacol 2010; 61(1): 45-52.
46. Woodman OL, Malakul W. 3',4'-Dihydroxyflavonol prevents diabetes-induced endothelial dysfunction in rat aorta. Life Sci 2009; 85(1-2): 54-9.
47. Wang Q, Yan J, Chen X, et al. Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2010; [Epub ahead of print].
48. Zhou J, Wang L, Ling S, Zhang X. Expression changes of growthassociated protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment rats. Exp Neurol 2007; 206 (2): 201-8.
49. Xu L, Li B, Cheng M, et al. Oral administration of grape seed proanthocyanidin extracts downregulate RAGE dependant nuclear factor- kappa BP65 expression in the hippocampus of streptozotocin induced diabetic rats. Exp Clin Endocrinol Diabetes 2008; 116(4): 215-24.
50. Saravia FE, Beauquis J, Revsin Y, Homo-Delarche F, de Kloet ER, De Nicola A.F. Hippocampal neuropathology of diabetes mellitus is relieved by estrogen treatment. Cell Mol Neurobiol 2006; 26(4-6): 943-57.
51. Luchsinger J.A. Type 2 Diabetes and related conditions in relation to dementia: An opportunity for prevention? J Alzheimers Dis 2010; 20(3): 723-36.
52. Isingrini E, Desmidt T, Belzung C, Camus V. Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease? Curr Opin Investig Drugs 2009; 10(1): 46-55.
53. Weseler AR, Bast A. Oxidative stress and vascular function: Implications for pharmacologic treatments. Curr Hypertens Rep 2010; 12(3): 154-61.
54. Ozkul A, Ayhan M, Yenisey C, Akyol A, Guney E, Ergin F.A. The role of oxidative stress and endothelial injury in diabetic neuropathy and neuropathic pain. Neuro Endocrinol Lett 2010; 31(2): 261-4.
55. Javeshghani D, Schiffrin EL, Sairam MR, Touyz R.M. Potentiation of vascular oxidative stress and nitric oxide-mediated endothelial dysfunction by high-fat diet in a mouse model of estrogen deficiency and hyperandrogenemia. J Am Soc Hypertens 2009; 3(5): 295-305.
56. Koladiya RU, Jaggi AS, Singh N, Sharma B. Beneficial effects of donepezil on vascular endothelial dysfunction-associated dementia induced by L-methionine in rats. J Health Sci 2009; 55(2): 215-25.
57. Park KW, Baik HH, Jin B.K. Interleukin-4-induced oxidative stress via microglial NADPH oxidase contributes to the death of hippocampal neurons in vivo. Curr Aging Sci 2008; 1(3): 192-201.
58. Shelat PB, Chalimoniuk M, Wang JH, et al. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 2008; 106(1): 45-55.
59. Didion SP, Faraci F.M. Effects of NADH and NADPH on superoxide levels and cerebral vascular tone. Am J Physiol Heart Circ Physiol 2002; 282: H688-H95.
60. Paravicini TM, Chrissobolis S, Drummond GR, Sobey C.G. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke 2004; 35: 584-9.
61. Park LJ, Anrather JP, Zhou PK, Frys K, Wang G, Iadecola C. Exogenous NADPH increases cerebral blood flow through NADPH oxidase-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol 2004; 24: 1860-5.
62. Miller AA, Drummond GR, Schmidt HHHW, Sobey C.G. NADPHoxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 2005; 97: 1055-62.
63. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-83.
64. Mohazzab K M, Kaminski P.M, Wolin M S. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994; 266: H2568-H72.
65. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23.
66. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen W.H. Ageing and diabetes: Implications for brain function. Eur J Pharmacol 2002; 441: 1-14.
67. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570-81.
68. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte P.M. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-74.
69. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 2004; 11(2): 89-97.
70. Guzik TJ, West NE, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-E90.
71. McGeer PL, McGeer E.G. The role of the immune system in neurodegenerative disorders. Mov Disord 1997; 12: 855-8.
72. Zekry D, Epperson TK, Krause K.H. A role for NOX NADPH oxidases in Alzheimer's disease and other types of dementia? IUBMB Life 2003; 55(6): 307-13.
73. Miller AA, Drummond GR, Sobey C.G. Novel isoforms of NADPH-oxidase in cerebral vascular control. Pharmacol Ther 2006; 111(3): 928-48.
74. Kimura N, Shimizu H, Eldawoody H, et al. Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats. Brain Res 2010; 1322: 144-52.
75. Mans RA, Chowdhury N, Cao D, McMahon LL, Li L. Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience 2010; 166(2): 435-44.
76. Reiss AB, Wirkowski E. Statins in neurological disorders: Mechanisms and therapeutic value. Sci World J 2009; 9: 1242-59.